Progress in endocrine approaches to the treatment and prevention of breast cancer.
Progress in endocrine approaches to the treatment and prevention of breast cancer.
复制标题
DOI：
10.1016/j.maturitas.2011.09.006
复制
发表时间：
2011-12
期刊：
影响因子：
4.9
通讯作者：
Jordan VC
中科院分区：
文献类型：
--
作者：
Obiorah I;Jordan VC
从1979年到2000年，他莫昔芬一直是乳腺癌全身治疗的唯一可用激素选择。巨大的努力已经导致开发了有效的和选择性的第三代芳香酶抑制剂，包括阿那曲唑、来曲唑和阿司美坦。由于其上级功效优于他莫昔芬，芳香酶抑制剂目前被批准作为治疗晚期雌激素受体（ER）阳性乳腺癌的一线药物和绝经后妇女中早期ER阳性早期乳腺癌的辅助疗法。选择性ER调节剂（SERMS），他莫昔芬和雷洛昔芬是目前用于预防高危女性乳腺癌的唯一药物，其使用在过去十年中大幅增加。与安慰剂相比，第三代SERMS、拉索昔芬和巴多昔芬在绝经后女性中显示出骨丢失显著减少，目前已在欧盟获批用于治疗绝经后骨质疏松症。这篇综述概述了目前使用内分泌治疗的管理和预防乳腺癌的策略。
Tamoxifen had been the only available hormonal option for the systemic treatment for breast cancer from 1979–2000. Enormous efforts have led to the development of potent and selective third generation aromatase inhibitors including anastrozole, letrozole and exemestane. Due to their superior efficacy to tamoxifen, aromatase inhibitors are presently approved as first line agents for the treatment of advanced estrogen receptor (ER) positive breast cancer and adjuvant therapy in early ER positive early breast cancer in postmenopausal women. Selective ER Modulators (SERMS), tamoxifen and raloxifene are the only agents presently used in breast cancer prevention in high risk women and their use has increased substantially over the last decade. Third generations SERMS, lasofoxifene and bazedoxifene have shown significant reduction in bone loss compared to placebo in postmenopausal women and are currently approved in the European Union for the treatment of postmenopausal osteoporosis. This review outlines the current strategies employed in the use of endocrine therapy in the management and prevention of breast cancer.
登录
查看更多内容
影响因子：
6.2
作者：
Cuppone, Federica;Bria, Emilio;Giannarelli, Diana
通讯作者：
Giannarelli, Diana
影响因子：
120.7
作者：
Cummings, SR;Eckert, S;Jordan, VC
通讯作者：
Jordan, VC
影响因子：
168.9
作者：
Davies, C.;Godwin, J.;Gray, R.;Clarke, M.;Darby, S.;McGale, P.;Wang, Y. C.;Peto, R.;Pan, H. C.;Cutter, D.;Taylor, C.;Ingle, J.
通讯作者：
Ingle, J.
影响因子：
45.3
作者：
Dowsett, Mitch;Cuzick, Jack;Peto, Richard
通讯作者：
Peto, Richard
影响因子：
11.5
作者：
Geisler, Jurgen;Helle, Hilgegunn;Lonning, Per E.
通讯作者：
Lonning, Per E.